Colorectal cancer studies at ASCO 2018
https://www.medscape.com/viewarticle/897370?nlid=122873_2201&src=WNL_mdplsnews_180601_mscpedit_honc&uac=155670BY&spon=7&impID=1647344&faf=1 #3509 (Geissler M et al. ) 2:1 random of 96 pts. (1st-line) mFOLFOXIRI + panitumumab vs. FOLFOXIRI in RAS-wt mCRC RR: 85.7% vs. 54.5% #3507 ctDNA assay in ~5,000 pts. #3505 (Pietrantonio F et al.) Unresectable RAS-wt mCRC FOLFOX + panitumumab X8 -> 1:1 random of 229 pts. panitumumab vs. panitumumab + FL (better) .. a couple of papers in the Lancet from the United Kingdom in which we randomized patients who were responding or had stable disease to stop or continue chemotherapy until progression. In those rather old-fashioned studies, having a complete chemotherapy break did not interfere or reduce overall survival. And not surprisingly, it was associated with improved quality of life. 1) And we tend to select patients for maintenance treatment who have a higher metastatic burden or tumor load on pre